Akari Therapeutics (AKTX) Total Liabilities (2011 - 2026)

Akari Therapeutics (AKTX) has 16 years of Total Liabilities data on file, last reported at $19.5 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 33.22% year-over-year to $19.5 million; the trailing twelve-month figure through Mar 2026 stood at $19.5 million (down 33.22% YoY), and the FY2025 full-year result was $19.6 million, down 30.95% from the prior year.
• Total Liabilities was little changed at $19.5 million in Q1 2026, from $19.6 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $29.2 million in Q1 2025 to a low of $2.7 million in Q3 2024.
• A 5-year average of $15.6 million and a median of $19.5 million in 2026 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities slumped 61.93% in 2023 and soared 953.86% in 2025, its largest moves.
• Tracing AKTX's Total Liabilities over 5 years: stood at $12.0 million in 2022, then sank by 61.93% to $4.6 million in 2023, then soared by 518.08% to $28.3 million in 2024, then plunged by 30.95% to $19.6 million in 2025, then declined by 0.28% to $19.5 million in 2026.
• Business Quant data shows AKTX's Total Liabilities at $19.5 million in Q1 2026, $19.6 million in Q4 2025, and $22.7 million in Q3 2025.